Showing results (531-540 of 887) with videos related to
Sort By:
Pageof 89
Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.Journal of Hypertension|March 16, 2012
Prevention of microalbuminuria in patients with type 2 diabetes and hypertensionJan Menne, Joseph L Izzo, Sadayoshi Ito, et al.Journal of the American Society of Nephrology : JASN|January 24, 2002
Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failureFlorian Kronenberg, Erich Kuen, Eberhard Ritz, et al.Journal of Molecular Medicine (Berlin, Germany)|September 17, 2008
Chronic low-dose isotretinoin treatment limits renal damage in subtotally nephrectomized ratsChristian Morath, Kerstin Ratzlaff, Claudius Dechow, et al.Diabetes Care|April 26, 2022
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical TrialsKatherine R Tuttle, Adeera Levin, Masaomi Nangaku, et al.Kidney International|May 31, 2019
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamicsGert J Mayer, Christoph Wanner, Matthew R Weir, et al.European Heart Journal|January 29, 2016
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialDavid Fitchett, Bernard Zinman, Christoph Wanner, et al.Circulation|September 15, 2017
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney DiseaseChristoph Wanner, John M Lachin, Silvio E Inzucchi, et al.European Heart Journal|December 30, 2021
Kidney function assessment and endpoint ascertainment in clinical trialsMuhammad Shahzeb Khan, George L Bakris, Milton Packer, et al.Diabetes & Vascular Disease Research|January 16, 2015
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsSilvio E Inzucchi, Bernard Zinman, Christoph Wanner, et al.Pageof 89